What type of study is this?

This is a Cohort Study study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

This study aims to compare mortality rates in heart failure with preserved ejection fraction (HFpEF) patients with an age- and gender-matched general population.

January 9, 2026GeroScienceOpen Access

Heart failure with preserved ejection fraction shows no excess mortality in older patients: a population-matched relative survival analysis

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Heart failure with preserved ejection fraction (HFpEF) (n=334). Primary outcome: All-cause mortality (SMR 3.37, 95% CI 2.4-4.7, p=<0.001).

View Full Paper

Ask AI

Bookmark

Key result

Younger HFpEF patients experience significantly higher mortality compared to age- and gender-matched counterparts, whereas older HFpEF patients have no excess mortality.

Authors

CTChristophe de TerwangneCliniques Universitaires Saint-Luc NMNassiba MenghoumCliniques Universitaires Saint-Luc MBMarin BouteCliniques Universitaires Saint-Luc

Discussion

Member takes

Implication

Cohort study compares mortality rates in heart failure patients with their age-matched peers, indicating no excess risk for older adults.

Key Points

This study aims to compare mortality rates in heart failure with preserved ejection fraction (HFpEF) patients with an age- and gender-matched general population.
Conducted a real-life cohort study of HFpEF patients with cardiac assessments since 2015.
Compared observed and expected mortality rates using standardised mortality ratios (SMR).
Divided participants into two age groups: < 80 years and ≥ 80 years.
108 out of 334 HFpEF patients died during a median follow-up of 4.1 years.
HFpEF patients < 80 years showed a three times higher mortality risk (SMR 3.37).
HFpEF patients ≥ 80 years had a similar mortality risk compared to the matched population (SMR 1.13).

Study Design

Type

Cohort (n=334)

Multicenter

PICO

Population

Heart failure with preserved ejection fraction (HFpEF) (n=334)

Primary Outcome

All-cause mortality — SMR 3.37 (2.4-4.7), p=<0.001

Main Result

Effect estimate: SMR 3.37 (95% CI 2.4-4.7)

p-value: p=<0.001

Limitations

Single-center study may limit generalizability.
Lack of frailty measurement in the cohort.

Cite This Study

Terwangne et al. (2026) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) (n=334). Younger HFpEF patients experience significantly higher mortality compared to age- and gender-matched counterparts, whereas older HFpEF patients have no excess mortality.

synapsesocial.com/papers/696128ef44c2cd6c68456c11 https://doi.org/10.1007/s11357-025-02063-0

View Full Paper

Ask AI

Bookmark